Introduction

FAMPAC Cells, also known by the synonyms FamPAC, Fampac, and PA-CLS-13, represent a uniquely valuable human pancreatic ductal adenocarcinoma cell line established from a patient with documented familial predisposition to pancreatic cancer. Eisold, Ryschich, and Linnebacher first characterized this line in 2004, making FAMPAC the first reported human pancreatic carcinoma cell line with a confirmed hereditary background. [1] In its founding characterization the line was defined by a TP53 p.Arg175His hotspot mutation and a homozygous deletion of the p16/CDKN2A tumor suppressor (with wild-type BRCA2), alterations central to pancreatic malignancy. FAMPAC grows as an adherent monolayer and forms tumors rapidly in nude mice, making it suitable for both in vitro mechanistic studies and in vivo tumorigenicity experiments. Researchers have applied this model to investigations spanning tumor suppressor gene biology, chemosensitivity profiling, oxidative stress pathways, and surgical device safety testing.

Key Takeaways

• FAMPAC is the first human pancreatic carcinoma cell line established with a confirmed familial/hereditary background.
• In the founding characterization the cell line showed a TP53 p.Arg175His mutation with overexpression of mutant p53, a homozygous p16/CDKN2A deletion, and wild-type BRCA2; KRAS was not assessed in that study. [1]
• FAMPAC grows as an adherent monolayer with a doubling time of 24–48 hours and forms tumors in immunodeficient mice.
• The model exhibits low basal Nrf2 expression, providing an informative contrast to Nrf2-high pancreatic cancer lines in pathway studies.
• FAMPAC has been employed across diverse research areas, including chemosensitivity profiling, oxidative stress biology, and intraoperative device safety evaluation.
• The Cellosaurus accession for FAMPAC is CVCL_5749; a clonal derivative, FAMPAC-A Cells (CVCL_5750), has also been established.

What Is FAMPAC?

FAMPAC was derived from the primary pancreatic adenocarcinoma of a 43-year-old female patient with a hereditary predisposition to pancreatic carcinoma, classified as familial pancreatic carcinoma. Eisold and colleagues characterized the line comprehensively at its establishment, assessing morphology, growth kinetics, tumorigenicity in nude mice, chromosomal composition, and the mutational status of three clinically important tumor suppressor genes: p16/CDKN2, BRCA2, and p53. [1] The cells grow as an adherent monolayer in serum-supplemented medium and display a doubling time of 24–48 hours.

Genetically, the founding characterization identified a TP53 p.Arg175His mutation (c.524G>A; exon 5, codon 175, CGC→CAC) accompanied by overexpression of the mutant p53 protein, a homozygous deletion of p16/CDKN2A, and wild-type BRCA2 at the tested hot spots. [1] The TP53 R175H alteration is a well-characterized hotspot that abrogates wild-type p53 tumor suppressor activity. Notably, KRAS — mutated in more than 90% of pancreatic ductal adenocarcinomas — was not analyzed in the original study; a KRAS mutation is annotated for FAMPAC in cell-line reference databases (Cellosaurus, CVCL_5749), but this annotation lies outside the primary characterization and is not independently confirmed here. Together, the verified alterations recapitulate key features of the pancreatic ductal adenocarcinoma genome and make FAMPAC a genetically defined model system.

Cell Culture Information

Advantages of FAMPAC Cells

The most distinctive advantage of FAMPAC is its origin from a patient with familial pancreatic carcinoma. This hereditary context is exceptionally rare among established pancreatic cancer cell lines and provides researchers with an opportunity to study the genetic underpinnings of heritable pancreatic cancer risk. Because familial pancreatic carcinoma accounts for approximately 5–10% of all cases and has distinct prognostic implications, a dedicated in vitro model fills an important gap not covered by sporadically derived lines. [1]

FAMPAC's defined mutational profile further enhances its utility. The TP53 R175H hotspot together with the homozygous p16/CDKN2A deletion provides a molecularly characterized backdrop for mechanistic experiments. [1] Genetically defined pancreatic cancer panels have more broadly been used to identify mutation-associated drug-response patterns. [4] Additionally, FAMPAC forms tumors in nude mice within a short timeframe, supporting translational xenograft studies that complement in vitro observations. The combination of rapid growth, straightforward adherent culture, and reliable tumorigenicity makes FAMPAC practically accessible for a wide range of experimental workflows.

FAMPAC's characteristically low basal Nrf2 expression distinguishes it from Nrf2-high pancreatic cancer cell lines in the same panel studies. [2] This property makes FAMPAC a useful internal contrast when dissecting the Nrf2/Keap1 axis. Researchers can compare Nrf2-dependent proliferative and cytoprotective effects in high-expressing lines directly against a low-expressing comparator. This experimental versatility extends FAMPAC's value beyond models focused solely on Nrf2 dysregulation.

Limitations of FAMPAC Cells

Like all established cancer cell lines, FAMPAC has undergone adaptation to in vitro conditions over successive passages. This process can lead to genomic drift that diverges from the original tumor's biology. Chromosomal instability, a hallmark of pancreatic ductal adenocarcinoma, may evolve further during long-term culture. Researchers should therefore verify key genetic markers—particularly TP53 and p16/CDKN2A status—periodically and ensure passage numbers are recorded and limited where possible.

Because FAMPAC carries a homozygous deletion of p16/CDKN2A, the line has lost CDKN2A function entirely and therefore cannot serve as a model for intact p16 signaling. [1] Additionally, as a single-donor cell line from a family with uncharacterized predisposition genes, FAMPAC may not represent the full diversity of hereditary pancreatic cancer syndromes. The causative germline variant responsible for the familial background had not been identified at the time of cell line establishment, limiting definitive genotype–phenotype conclusions.

Safety testing experiments have noted that phosphate-buffered saline exerts a mild cytotoxic effect on FAMPAC cells, suggesting this line may respond differently to vehicle solutions compared with other pancreatic cell lines. [3] This sensitivity must be accounted for when designing cytotoxicity assays, selecting solvent controls, or interpreting cell viability data. Standard assumptions valid for other pancreatic lines should therefore be verified empirically in FAMPAC before drawing conclusions.

STR-authenticated, mycoplasma-free, ready to ship. View full specifications and order here

Applications

Hereditary Pancreatic Cancer Biology and Tumor Suppressor Genes

FAMPAC was conceived as a tool to investigate the biology of familial pancreatic carcinoma. The founding study by Eisold et al. analyzed three tumor suppressor genes—p16/CDKN2, BRCA2, and p53—that are frequently mutated in pancreatic cancer and implicated in hereditary cancer syndromes. [1] The rationale was that identifying which suppressor pathways are disrupted in a familially predisposed tumor could shed light on the yet-uncharacterized germline variants driving familial risk.

The TP53 R175H mutation in FAMPAC—accompanied by the overexpression of mutant p53 reported at its establishment [1]—has been studied in the context of adenovirus-mediated wild-type p53 restoration. In a panel that included FAMPAC (p53-mutant), combining adenoviral wild-type p53 transfer with 5-fluorouracil inhibited tumor-cell proliferation and enhanced apoptosis most strongly in the p53-altered lines, illustrating how p53 gene status modulates 5-fluorouracil chemosensitivity across pancreatic cancer cell lines. [5]

Invasion and migration are central to pancreatic cancer progression, and matrix biology is a recurring theme in pancreatic carcinoma models. Work from the group that established FAMPAC demonstrated that basement-membrane proteins—laminin, fibronectin, and collagen IV—promote β1-integrin-dependent migration of pancreatic carcinoma cells and drive their affinity for perineural invasion. [7] Such matrix-driven migration assays provide a framework directly relevant to how lines like FAMPAC are used to model invasion and to test anti-migratory strategies.

Oxidative Stress and Nrf2 Pathway Research

The Nrf2/Keap1 axis governs cellular defense against oxidative stress and modulates drug metabolism. Lister and colleagues examined this pathway across a panel of five pancreatic cancer cell lines, finding that Nrf2 was broadly overexpressed and that its depletion via RNAi reduced proliferation in most lines. [2] FAMPAC proved particularly informative in this study because it exhibited characteristically low basal Nrf2 expression and activity compared with other lines in the panel, providing a critical low-expression reference point.

Crucially, siRNA-mediated depletion of Nrf2 in FAMPAC produced no significant changes in glutathione (GSH) levels, in direct contrast to Nrf2-high lines where GSH was markedly reduced. [2] This finding demonstrated that Nrf2-independent mechanisms maintain redox homeostasis in low-Nrf2 pancreatic cancer cells, a mechanistic distinction with direct implications for therapeutic strategies targeting oxidative stress. The study's contribution to understanding Nrf2-driven pancreatic cancer biology has made it one of the most widely cited works to employ FAMPAC.

Mutation analysis in the same study found no mutations in NRF2 exon 2 and only synonymous variants in KEAP1 exons 2–6 across the panel, including FAMPAC. This suggested that in FAMPAC, aberrant Nrf2 pathway activity—where present—arises from mechanisms beyond direct coding mutations in these canonical regulatory genes. These observations reinforce FAMPAC's value in dissecting non-mutational modes of pathway regulation in pancreatic cancer.

Chemosensitivity and Drug Response Profiling

Pancreatic ductal adenocarcinoma responds poorly to most chemotherapeutic regimens, and identifying genetic predictors of drug sensitivity is a priority. The broader value of stratifying pancreatic cancer cell lines by genotype was demonstrated by Cui and colleagues, who screened a genetically defined panel against eight compounds spanning multiple mechanistic classes—gemcitabine, docetaxel, mitomycin C, irinotecan, cisplatin, a PARP1 inhibitor, triptolide, and artemisinin (the negative control)—and found all lines sensitive to triptolide and docetaxel, while responses to the other agents tracked with specific genetic defects such as DPC4/SMAD4, TP53, and p16/CDKN2A status. [4] That panel comprised Johns Hopkins–derived pancreatic cancer lines and did not include FAMPAC itself.

FAMPAC's own drug responses have, however, been examined directly. In the Nrf2 study, siRNA-mediated Nrf2 depletion significantly increased FAMPAC's sensitivity to 5-fluorouracil and cisplatin, identifying the Nrf2/Keap1 axis as a modulator of chemoresistance in this line. [2] Earlier work from the group that established FAMPAC showed that adenoviral transfer of wild-type p53 combined with 5-fluorouracil enhanced apoptosis most strongly in p53-defective lines, with FAMPAC (p53-mutant) among the cell lines tested. [5]

More recently, a large phenotypic screen tested 13 pancreatic ductal adenocarcinoma cell lines—FAMPAC among them—against gemcitabine in combination with 146 clinical inhibitors, identifying strong synergy between gemcitabine and the ATR kinase inhibitor elimusertib in 12 of the 13 lines; dose-resolved phosphoproteomics in the same study pinpointed a block of the DNA-damage-response pathway, including CHEK1 phosphorylation, as the underlying mechanism. [6] This places FAMPAC within the evidence base supporting ATR inhibition as a strategy to overcome gemcitabine resistance.

Surgical Device and Biomaterial Safety Testing

FAMPAC has been applied as a relevant pancreatic cancer cell model in the preclinical safety evaluation of intraoperative surgical materials. Pausch and colleagues used FAMPAC alongside normal human pancreatic duct epithelial cells to test the cytotoxicity of SmartPAN, a hydrogel designed to detect and seal pancreatic fistulas intraoperatively. [3] Resazurin-based viability assays showed that SmartPAN's active bromothymol blue indicator caused no significant reduction in FAMPAC cell viability below established safety thresholds.

Interestingly, the PBS vehicle used to prepare SmartPAN produced a mild cytotoxic effect specifically in FAMPAC cells but not in the normal pancreatic epithelial comparator, highlighting the cell line's relative sensitivity to ionic composition changes. [3] This distinction was important for interpreting safety data, as it required investigators to account for vehicle effects separately from the active compound's biological impact. Including FAMPAC alongside a normal cell comparator enabled a more rigorous assessment of therapeutic index before human trials.

This application illustrates how FAMPAC extends beyond classical oncology research into the preclinical device and biomaterial safety space. Its use as a carcinoma cell comparator in cytotoxicity assays provides a worst-case scenario perspective—if a material is safe in both normal and tumor-derived pancreatic cells, confidence in proceeding to clinical evaluation is strengthened. Such applications are likely to expand as more pancreas-targeted surgical innovations require pancreatic cell line validation.

Emerging Therapeutic Targets in Pancreatic Cancer

Looking ahead, FAMPAC's defined molecular features make it a candidate model for several emerging strategies. Heat shock proteins such as HSP70 are increasingly pursued as apoptosis-modulating anticancer targets, and a pancreatic line carrying a gain-of-function TP53 hotspot is a plausible system for testing whether HSP-directed agents can overcome the apoptotic resistance associated with mutant p53. Likewise, because oncogenic KRAS drives the overwhelming majority of pancreatic ductal adenocarcinomas, FAMPAC and comparable exocrine models are relevant to the broad effort to inhibit RAS signaling directly—though, as noted above, FAMPAC's own KRAS status was not part of its primary characterization. These directions are exploratory: to our knowledge FAMPAC has not yet been reported as a test line in these specific programs, and the framing here reflects biological rationale rather than published results in this cell line.

Conclusion

FAMPAC stands as a distinctive and well-characterized human pancreatic ductal adenocarcinoma cell line, notable for its origins in a patient with documented familial pancreatic carcinoma. Its defined TP53 R175H mutation and homozygous p16/CDKN2A deletion, adherent growth properties, in vivo tumorigenicity, and low basal Nrf2 expression collectively make it a versatile model for hereditary pancreatic cancer research, chemosensitivity profiling, oxidative stress pathway studies, and biomaterial safety evaluation. The diversity of research contexts in which FAMPAC has contributed—from foundational tumor suppressor gene analysis to intraoperative hydrogel testing—underscores the broad utility of this rare hereditary model. Researchers seeking a genetically defined pancreatic cancer system with a familial background will find FAMPAC an important and complementary addition to their in vitro toolkit. To explore full product specifications or to order FAMPAC cells for your research, visit cytion.com.

Key Publications

1. Eisold S, Ryschich E, Linnebacher M, et al. (2004) Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer. PMID: 15112280
2. Lister A, Nedjadi T, Kitteringham NR, et al. (2011) Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer. PMID: 21489257
3. Pausch TM, Bartel M, Cui J, et al. (2022) SmartPAN: In vitro and in vivo proof-of-safety assessments for an intra-operative predictive indicator of postoperative pancreatic fistula. Basic & Clinical Pharmacology & Toxicology. PMID: 35040273
4. Cui Y, Brosnan JA, Blackford AL, et al. (2012) Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clinical Cancer Research. PMID: 22753594
5. Eisold S, Linnebacher M, Ryschich E, et al. (2004) The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World Journal of Gastroenterology. PMID: 15534911
6. Höfer S, Frasch L, Brajkovic S, et al. (2025) Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Molecular Systems Biology. PMID: 39838187
7. Ryschich E, Khamidjanov A, Kerkadze V, et al. (2009) Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer. Pancreas. PMID: 19893454